CS585 attenuates ex vivo platelet adhesion and thrombus formation under flow. (A) Human whole blood treated with vehicle or CS585 (0.062-5 μM) was perfused on a collagen-coated PL chip at arterial shear using T-TAS (n = 5). Data represent mean ± SEM. One-way ANOVA with Dunnett correction. (B) Quantification and representative images of platelet adhesion and accumulation in human whole blood stained with DiOC6 and treated with vehicle or CS585 (250 nM-1 μM) perfused through a collagen-coated chamber at arterial shear (n = 6). Data represent mean ± SEM. Two-way ANOVA. Scale bars represent 100 μm. (C) Human whole blood treated with vehicle or iloprost (0.125-2.5 nM) and then perfused on a collagen-coated PL chip at arterial shear using T-TAS (n = 5). Data represent mean ± SEM. One-way ANOVA with Dunnett correction. (D) Quantification and representative images of platelet adhesion and accumulation of human whole blood stained with DiOC6 and treated with vehicle or iloprost (0.25-1 nM) perfused through a collagen-coated chamber at arterial shear (n = 6). Data represent mean ± SEM. Two-way ANOVA. Scale bars represent 100 μm. (E) Human whole blood treated with vehicle or an IP receptor inhibitor (Ro 1138542, 5 μM) before treatment with vehicle or CS585 (1 μM) perfused on a collagen-coated PL chip at arterial shear using T-TAS (n = 5). Data represent mean ± SEM. One-way ANOVA with Tukey multiple comparison test. (F) Quantification and representative images of platelet adhesion and accumulation in human whole blood stained with DiOC6 and treated with vehicle or an IP receptor inhibitor (Ro 1138542, 5 μM) before treatment with vehicle or CS585 (1 μM) perfused through a collagen-coated chamber under arterial shear (n = 6). Data represent mean ± SEM. Two-way ANOVA. Scale bars represent 100 μm. (G) Quantification and representative contour plots of phosphatidylserine exposure in washed human platelets treated with vehicle, CS585 (100 nM), or iloprost (20 nM), incubated with annexin V and an antibody for CD62P, then stimulated with 0.5 nM thrombin or 50 ng/mL (n = 5). Data represent mean percentage of dual-positive platelets ± SEM. One-way ANOVA with Tukey multiple comparison test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.

CS585 attenuates ex vivo platelet adhesion and thrombus formation under flow. (A) Human whole blood treated with vehicle or CS585 (0.062-5 μM) was perfused on a collagen-coated PL chip at arterial shear using T-TAS (n = 5). Data represent mean ± SEM. One-way ANOVA with Dunnett correction. (B) Quantification and representative images of platelet adhesion and accumulation in human whole blood stained with DiOC6 and treated with vehicle or CS585 (250 nM-1 μM) perfused through a collagen-coated chamber at arterial shear (n = 6). Data represent mean ± SEM. Two-way ANOVA. Scale bars represent 100 μm. (C) Human whole blood treated with vehicle or iloprost (0.125-2.5 nM) and then perfused on a collagen-coated PL chip at arterial shear using T-TAS (n = 5). Data represent mean ± SEM. One-way ANOVA with Dunnett correction. (D) Quantification and representative images of platelet adhesion and accumulation of human whole blood stained with DiOC6 and treated with vehicle or iloprost (0.25-1 nM) perfused through a collagen-coated chamber at arterial shear (n = 6). Data represent mean ± SEM. Two-way ANOVA. Scale bars represent 100 μm. (E) Human whole blood treated with vehicle or an IP receptor inhibitor (Ro 1138542, 5 μM) before treatment with vehicle or CS585 (1 μM) perfused on a collagen-coated PL chip at arterial shear using T-TAS (n = 5). Data represent mean ± SEM. One-way ANOVA with Tukey multiple comparison test. (F) Quantification and representative images of platelet adhesion and accumulation in human whole blood stained with DiOC6 and treated with vehicle or an IP receptor inhibitor (Ro 1138542, 5 μM) before treatment with vehicle or CS585 (1 μM) perfused through a collagen-coated chamber under arterial shear (n = 6). Data represent mean ± SEM. Two-way ANOVA. Scale bars represent 100 μm. (G) Quantification and representative contour plots of phosphatidylserine exposure in washed human platelets treated with vehicle, CS585 (100 nM), or iloprost (20 nM), incubated with annexin V and an antibody for CD62P, then stimulated with 0.5 nM thrombin or 50 ng/mL (n = 5). Data represent mean percentage of dual-positive platelets ± SEM. One-way ANOVA with Tukey multiple comparison test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal